Sai Parenterals Limited has appointed new auditors for the financial year 2026-27 and authorized its Managing Director to explore strategic growth opportunities. The decisions were taken during a board meeting held on July 06, 2026, at the company's registered office. These appointments are subject to necessary regulatory approvals and shareholder consent where applicable.

Auditor Appointments

The board approved the appointment of M/s. Aakanksha Dubey & Co., Practicing Company Secretaries, as Secretarial Auditors for a period of five financial years, from 2026-27 to 2030-31. This appointment is subject to the approval of shareholders. For the financial year 2026-27, the board appointed M/s. NSVR & Associates LLP, Chartered Accountants, as Internal Auditors and M/s. Sai Krishna & Associates, Cost Accountants, as Cost Auditors.

Strategic Authorization

In addition to the auditor appointments, the board authorized Mr. Anil Kumar Karusala, Chairman & Managing Director, to identify, evaluate, and explore suitable organic and inorganic growth opportunities. This mandate covers the existing line of business as well as other strategic areas deemed beneficial to the company.

Appointment Details

Sai Parenterals Limited 's subsidiary Noumed Pharmaceuticals Pty Limited has secured an exclusive Over-The-Counter (OTC) medicine supply agreement with Australia’s leading pharmacy network. The contract is valued at Australian Dollars (AUD) 202 Million, equivalent to INR 1300 crores, based on an exchange rate of 1 AUD = INR 64.5. This long-term agreement is effective from July 1, 2026, and is expected to significantly bolster the subsidiary's revenue streams over the contract period.

The agreement spans an initial term of 7.5 years, with a provision for a further extension of 3 years upon mutual consent between the parties involved. The deal translates to approximately AUD 27 Million per annum and includes a provision to add 12 new products every year, steadily increasing the contract's value and scope. The order has been awarded by an international entity, and the nature of the transaction is classified as an exclusive supply agreement. The company confirmed that the promoters, promoter group, or group companies do not hold any interest in the entity awarding the contract.

Key Contract Details

Strategic Benefits

The renewed agreement delivers substantial, multi-layered value by locking in predictable, recurring revenues across the 7½-year horizon. It further cements Noumed's presence in the Australian OTC market and expands Sai Parenterals' international pharmaceutical business. The agreement enhances manufacturing scale and operating leverage while supporting the continuous launch of new OTC products under leading Australian pharmacy brands.

Sai Parenterals clarified that the transaction does not fall within related party transactions and is conducted at arm's length. The disclosure was made to the exchanges in compliance with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The requisite details were provided in accordance with the SEBI Master Circular dated January 30, 2026.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE0H9F01037/32f7d35b8f3e4308.pdf